Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and ...

A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...

Helen Heslop and colleagues conducted a phase 1 clinical trial involving 19 children with neuroblastoma, between 2004 and ...

Y-mAbs Therapeutics, Inc. has presented preclinical and translational pharmacokinetic data of their GD2-SADA bispecific fusion protein at the 2025 Society of Nuclear Medicine & Molecular Imaging ...

The treatment was tailored to target GD2, a marker found in DIPG cells. Although the therapy caused some initial side effects like fever and inflammation, patients showed notable progress.

An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent the longest reported ...

(RTTNews) - Y-mAbs Therapeutics, Inc. (YMAB), a commercial-stage biopharmaceutical company presented preclinical and translational pharmacokinetics or PK data of GD2-SADA at the 2025 SNMMI Mid ...

More information: Helen Heslop et al, Long-term outcomes of GD2-directed CAR-T cell therapy in patients with neuroblastoma, Nature Medicine (2025). DOI: 10.1038/s41591-025-03513-0 Provided by ...